Steven Cohen Arrowhead Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $2,541 - $3,499	-97 Reduced 10.68%	811 $21,000
Q2 2023 Aug 14, 2023	BUY	$25.16 - $41.38 $22,845 - $37,573	908 New	908 $32,000
Q1 2023 May 15, 2023	SELL	$23.68 - $38.51 $1.34 Million - $2.18 Million	-56,652 Closed	0 $0
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $17.1 Million - $24.7 Million	-609,948 Reduced 91.5%	56,652 $2.3 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $8.02 Million - $13.1 Million	270,732 Added 68.39%	666,600 $22 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $4.59 Million - $8.36 Million	-165,232 Reduced 29.45%	395,868 $13.9 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $20.5 Million - $36.2 Million	516,808 Added 1166.82%	561,100 $25.8 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $6.75 Million - $9.59 Million	-116,208 Reduced 72.4%	44,292 $2.94 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $6.11 Million - $8.89 Million	104,600 Added 187.12%	160,500 $10 Million
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $3.47 Million - $5.05 Million	55,900 New	55,900 $4.63 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $58.4 Million - $114 Million	-1,332,899 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$33.21 - $51.27 $4.75 Million - $7.34 Million	143,092 Added 12.03%	1,332,899 $57.4 Million
Q2 2020 Aug 14, 2020	BUY	$26.12 - $43.27 $31.1 Million - $51.5 Million	1,189,807 New	1,189,807 $51.4 Million
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $158,560 - $262,175	-9,097 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $109,618 - $183,577	9,097 New	9,097 $167,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account